Systematic Review of Adverse Events of Buprenorphine Patch Versus Fentanyl Patch in Patients with Chronic Moderate-To-Severe Pain

• Reid KJ , HarkerJ, BalaMM et al. Epidemiology of chronic non-cancer pain in Europe. narrative review of prevalence, pain treatments and pain impact. Curr. Med. Res. Opin. 27(2) , 449–462 (2011).
   PubMed Web of Science ®Google Scholar
• Opioids in Cancer Pain. Davis M, Glare P, Hardy J (Eds). Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Bekkering GE , Soares-WeiserK, ReidK et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. Curr. Med. Res. Opin. 27(7) , 1477–1491 (2011).
   PubMed Web of Science ®Google Scholar
• Macdiarmid SA . The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Urol.11(1) , 1–6 (2009).
   PubMedGoogle Scholar
• Small G , DuboisB. A review of compliance to treatment in Alzheimer‘s disease: potential benefits of a transdermal patch. Curr. Med. Res. Opin.23(11) , 2705–2713 (2007).
   PubMed Web of Science ®Google Scholar
• Sorge J , SittlR. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther.26(11) , 1808–1820 (2004).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , AloisiAM, DahanA et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 10(5) , 428–450 (2010).
   PubMed Web of Science ®Google Scholar
• Wolff RF , AuneD, TruyersC, HernandezAV, MissoK, RiemsmaR, KleijnenJ. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr. Med. Res. Opin28(5) , 833–845 (2012).
   PubMed Web of Science ®Google Scholar
• Riemsma R , ForbesC, HarkerJ et al. Systematic review of tapentadol in chronic severe pain. Curr. Med. Res. Opin. 27(10) , 1907–1930 (2011).
   PubMed Web of Science ®Google Scholar
• Allan L , KalsoE. Randomized trial of transdermal fentanyl and sustained release oral morphine in chronic low back pain. Presented at: Pain in Europe IV. Fourth Congress of the European Federation of IASP Chapters (EFIC). Prague, Czech Republic, 2–6 September 2003.
   Google Scholar
• Allan L , RicharzU, SimpsonK, SlappendelR. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine30(22) , 2484–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Hartung DM , MiddletonL, HaxbyDG, KoderM, KetchumKL, ChouR. Rates of adverse events of long-acting opioids in a state medicaid program. Ann. Pharmacother.41(6) , 921–928 (2007).
   PubMed Web of Science ®Google Scholar
• Kongsgaard U , PoulainP. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur. J. Pain2(1) , 53–62 (1998).
   PubMed Web of Science ®Google Scholar
• Kongsgaard UE , PoulainP. Transdermal fentanyl for pain control in chronic cancer pain. Support Care Cancer5(Suppl. 1) , 177 (1997).
   Google Scholar
• Kress HG , Von Der Laage D, Hoerauf KH et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J. Pain Symptom Manage.36(3) , 268–279 (2008).
   PubMed Web of Science ®Google Scholar
• Lauretti GR , MatsumotoM, De Mattos AL, Lanchote V, Pereira NL. Avaliação clínica e laboratorial da cetamina transdérmica, do fentanil transdérmico, da clonidina transdérmica ou suas associações na dor lombar crônica. Evaluación clínica y de laboratorio de cetamina transdérmica, del fentanyl transdérmico, de la clonidina transdérmica o de sus asociaciones en el dolor lumbar crónico. Coluna/Columna8(4) , 434–440 (2009).
   Google Scholar
• Niemann T , MadsenLG, LarsenS, ThorsgaardN. Opioid treatment of painful chronic pancreatitis. Int. J. Pancreatol.27(3) , 235–240 (2000).
   PubMedGoogle Scholar
• Van Seventer R , SmitJM, SchipperRM, WicksMA, ZuurmondWW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr. Med. Res. Opin.19(6) , 457–469 (2003).
   PubMed Web of Science ®Google Scholar
• Griessinger N , SittlR, LikarR. Transdermal buprenorphine in clinical practice – a post-marketing surveillance study in 13179 patients. Curr. Med. Res. Opin.21(8) , 1147–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Langford R , MckennaF, RatcliffeS, VojtassakJ, RicharzU. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum.54(6) , 1829–1837 (2006).
   PubMedGoogle Scholar
• Radbruch L , ElsnerF. Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J. Med.53(1) , 23–29 (2004).
   PubMedGoogle Scholar
• Radbruch L , SabatowskiR, PetzkeF, Brunsch-RadbruchA, GrondS, LehmannKA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat. Med.15(4) , 309–321 (2001).
   PubMed Web of Science ®Google Scholar
• Sarhan T , DoghemM. A comparison of two trans-dermal drug delivery systems; buprenorphine and fentanyl for chronic cancer pain management. Presented at: Pain in Europe VI: Sixth Congress of the European Federation of IASP Chapters (EFIC). Lisbon, Portugal, 9–12 September 2009.
   Google Scholar
• Schmidt-Grendelmeier P , PokornyR, GasserUE, RicharzU. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr. Med. Res. Opin.22(3) , 501–509 (2006).
   PubMed Web of Science ®Google Scholar
• Sittl R , GriessingerN, LikarR. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther.25(1) , 150–168 (2003).
   PubMed Web of Science ®Google Scholar
• Tschirner M , RitzdorfI, BrunjesR. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. MMW Fortschr. Med.150(Suppl. 3) , 142–148 (2008).
   PubMedGoogle Scholar
• Mystakidou K , ParpaE, TsilikaE et al. Pain management of cancer patients with transdermal fentanyl. A study of 1828 step I, II, and III transfers: erratum. J. Pain 5(9) , 528 (2004).
   Web of Science ®Google Scholar
• Mystakidou K , ParpaE, TsilikaE et al. Pain management of cancer patients with transdermal fentanyl. A study of 1828 step I, II, & III transfers. J. Pain 5(2) , 119–132 (2004).
   PubMed Web of Science ®Google Scholar
• Mercadante S , PorzioG, FulfaroF et al. Switching from transdermal drugs. An observational “N of 1” study of fentanyl and buprenorphine. J. Pain Symptom Manage. 34(5) , 532–538 (2007).
   PubMed Web of Science ®Google Scholar
• Muriel Villoria C , Cervera Grau JM, Constela Figueras M, Sanchez Magro I, Neira Alvarez M. [Evaluation of transdermal buprenorphine for the treatment of chronic pain in cancer patients]. Revista de la Sociedad Espanola del Dolor15(5) (2008).
   Google Scholar
• Muriel C , FaildeI, MicóJA, NeiraM, Sánchez-MagroI. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin. Ther.27(4) , 451–462 (2005).
   PubMed Web of Science ®Google Scholar
• Muriel Villoria C , Pérez-Castejón Garrote JM, Sánchez Magro I, Neira Álvarez M. [Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study]. Medicina Clinica128(6) , 204–210 (2007).
   PubMed Web of Science ®Google Scholar
• Ozturk T , KaradibakK, CatalD, CakanA, TugsavulF, CirakK. [Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer]. Agri. Derg.20(3) , 20–25 (2008).
   PubMedGoogle Scholar
• Apolone G , CorliO, NegriE, ManganoS, MontanariM, GrecoMT. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: Results from the cancer pain outcome research (CPOR) study group. Clin. J. Pain25(8) , 671–682 (2009).
   PubMed Web of Science ®Google Scholar
• Aurilio B , PaceMC, PassavantiMB. Transdermal buprenorphine combined with spinal morphine and naropine for pain relief in chronic peripheral vasculopathy. Minerva Anestesiol.71(7–8) , 445–449 (2005).
   PubMedGoogle Scholar
• Likar R , VadlauEM, BreschanC, KagerI, Korak-LeiterM, ZiervogelG. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin. J. Pain24(6) , 536–543 (2008).
   PubMed Web of Science ®Google Scholar
• Pace MC , PassavantiMB, GrellaE et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front. Biosci. 12 , 1291–1299 (2007).
   PubMed Web of Science ®Google Scholar
• Poulain P , DenierW, DoumaJ et al. Efficacy and safety of transdermal buprenorphine. A randomized, placebo-controlled trial in 289 patients with severe cancer pain. J. Pain. Symptom Manage. 36(2) , 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Wong JO , ChiuGL, TsaoCJ, ChangCL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol. Sin.35(1) , 25–32 (1997).
   PubMedGoogle Scholar
• Barutell C , CambaA, Gonzalez-EscaladaJR, RodriguezM. High dose transdermal buprenorphine for moderate to severe pain in Spanish pain centres – a retrospective multicenter safety and efficacy study. Pain Pract.8(5) , 355–361 (2008).
   PubMedGoogle Scholar
• Zuurmond W , DavisC, VergidisD. Transdermal fentanyl shows a similar safety and efficacy profile in elderly and non-elderly patients with cancer pain. Ann. Oncol.13(Suppl. 5) , 171 (2002) (Abstract 630).
   PubMed Web of Science ®Google Scholar
• Zuurmond W , DavisC. Safety and efficacy of transdermal fentanyl (Durogesic) compared with sustained-release morphine in patients with cancer pain. Proc. Am. Soc. Clin. Oncol.21(Pt 1) , 377a (2002) (Abstract 1506).
   Google Scholar
• Staats PS , MarkowitzJ, ScheinJ. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med. J.97(2) , 129–134 (2004).
   PubMed Web of Science ®Google Scholar
• Allan L , HaysH, JensenNH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322(7295) , 1154–1158 (2001).
   PubMed Web of Science ®Google Scholar
• Berger A , HoffmanDL, GoodmanS, DeleaTE, SeifeldinR, OsterG. Therapy switching in patients receiving long-acting opioids. Ann. Pharmacother.38(3) , 389–395 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmedzai S . TTS-fentanyl vs oral morphine in cancer pain. Eur. J. Cancer31(Suppl. 6) , S182 (1995) (Abstract 874).
   Google Scholar
• Ahmedzai S , BrooksD. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J. Pain Symptom Manage.13(5) , 254–261 (1997).
   PubMed Web of Science ®Google Scholar
• Aurilio C , PaceMC, PotaV et al. Opioids switching with transdermal systems in chronic cancer pain. J. Exp. Clin. Cancer Res. 28(1) , 61 (2009).
   PubMedGoogle Scholar
• Dagtekin O , GerbershagenHJ, WagnerW, PetzkeF, RadbruchL, SabatowskiR. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesthesia Analgesia105(5) , 1442–1448 (2007).
   PubMed Web of Science ®Google Scholar
• Filitz J , GriessingerN, SittlR, LikarR, SchüttlerJ, KoppertW. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur. J. Pain10(8) , 743–748 (2006).
   PubMed Web of Science ®Google Scholar
• Koppert W , IhmsenH, KörberN, WehrfritzA, SittlR, SchüttlerJ. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain118 , 15–22 (2005).
   PubMed Web of Science ®Google Scholar
• Mordarski S . Efficacy and safety of buprenorphine in patients receiving haemodialysis. J. Appl. Ther. Res.7(2) , 46–51 (2009).
   Google Scholar
• Budd K . Immunosuppressive effects induced by opioid analgesics. Int. Monit. Regional Anaesthesia Pain Manage.14 , 3–7 (2002).
   Google Scholar
• Dahan A . Respiratory depression with opioids. J. Pain Palliat. Care Pharmacother.21(1) , 63–66 (2007).
   PubMedGoogle Scholar
• Johnson RE , FudalaPJ, PayneR. Buprenorphine: considerations for pain management. J. Pain Symptom Manage.29(3) , 297–326 (2005).
   PubMed Web of Science ®Google Scholar
• Kotowa W , VoelklM, HassB, Poulsen Nautrup B. Estimated costs associated with different fracture risks related to opioid treatment in Germany. Value in Health10(3) , A172 (2007).
   Google Scholar
• Kress HG . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur. J. Pain13(3) , 219–230 (2009).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J , BogerRH, BuddK et al. Opioids and the management of chronic severe pain in the elderly. Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8(4) , 287–313 (2008).
   PubMedGoogle Scholar
• Pergolizzi J r JV. The use of high-dose transdermal buprenorphine in the treatment of cancer pain. J. Med.2(2) , 111–120 (2009).
   Google Scholar
• Dahan A , YassenA, BijiH et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesthesia 94(6) , 825–834 (2005).
   PubMed Web of Science ®Google Scholar
• Likar R , KrainerB, SittlR. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Int. J. Cancer62(1) , 152–156 (2008).
   Google Scholar
• Likar R , SittlR. Transdermal buprenorphine for treating nociceptive and neuropathic pain: Four case studies. Anesth. Analg.100(3) , 781–785 (2005).
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Mercadante S, Echaburu AV et al. The role of transdermal buprenorphine in the treatment of cancer pain. An expert panel consensus. Curr. Med. Res. Opin.25(6) , 1517–1528 (2009).
   PubMed Web of Science ®Google Scholar
• Freye E , Anderson-HillemacherA, RitzdorfI, LevyJV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract.7(2) , 123–129 (2007).
   PubMedGoogle Scholar
• Schulz KF , AltmanDG, MoherD, GroupC. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med.7(3) , e1000251 (2010).
   PubMed Web of Science ®Google Scholar

▪ Websites

• WHO. WHO‘s pain ladder. www.who.int/cancer/palliative/painladder/en/
   Google Scholar
• Joint Formulary Committee. British National Formulary (2010). www.bnf.org/bnf/index.htm
   Google Scholar
• Medsafe. New Zealand Medicines and Medical Devices Safety Authority. DBL RRR Fentanyl (2008). www.medsafe.govt.nz/profs/datasheet/d/dblfentanylinj.pdf
   Google Scholar
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Higgins JPT, Green S (Eds). The Cochrane Collaboration (2011). www.cochrane-handbook.org
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD‘s guidance for undertaking reviews in health care. University of York, UK (2009). www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm
   Google Scholar